A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study is to evaluate the safety and tolerability of AZD0530 in Japanese patients with advanced solid malignancies by assessment of AEs, vital signs, ECG, laboratory findings, thoracic imaging and pulmonary function test.
Assessed on an ongoing basis after starting daily dosing with AZD0530
Yes
Mary Stuart, MD
Study Chair
AstraZeneca
Japan: Ministry of Health, Labor and Welfare
D8180C00021
NCT00704366
June 2008
May 2011
Name | Location |
---|